Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2004

01-07-2004 | Article

Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial

Authors: K. L. Margolis, D. E. Bonds, R. J. Rodabough, L. Tinker, L. S. Phillips, C. Allen, T. Bassford, G. Burke, J. Torrens, B. V. Howard, for the Women’s Health Initiative Investigators

Published in: Diabetologia | Issue 7/2004

Login to get access

Abstract

Aims/hypothesis

Studies examining the effect of postmenopausal hormone therapy on concentrations of glucose, insulin and diabetes incidence have been inconclusive, in part because many of the studies were too small. We examined the effect of oestrogen plus progestin on diabetes incidence and insulin resistance.

Methods

The study was a randomised, double-blind trial comparing the effect of daily 0.625 mg conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate with that of placebo during 5.6 years of follow-up. The participants were 15,641 postmenopausal women enrolled in the Women’s Health Initiative Hormone Trial. These women were aged 50 to 79 and all had an intact uterus. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin, and lipoproteins were measured in a random sample at baseline and at 1 and 3 years.

Results

The cumulative incidence of treated diabetes was 3.5% in the hormone therapy group and 4.2% in the placebo group (hazard ratio 0.79, 95% CI 0.67–0.93, p=0.004). There was little change in the hazard ratio after adjustment for changes in BMI and waist circumference. During the first year of follow-up, changes in fasting glucose and insulin indicated a significant fall in insulin resistance in actively treated women compared to the control subjects (Year 1 to baseline between-group difference −0.22±0.10, p=0.03).

Interpretations/conclusion

These data suggest that combined therapy with oestrogen and progestin reduces the incidence of diabetes, possibly mediated by a decrease in insulin resistance unrelated to body size. Future studies of alternative postmenopausal hormone therapy regimens and selective oestrogen agonists and/or antagonists should consider the effects of these regimens on insulin resistance and diabetes.
Appendix
Available only for authorised users
Literature
1.
Mokdad A, Ford E, Bowman B et al. (2003) Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA 289:76–79CrossRefPubMed
2.
Espeland M, Hogan P, Fineberg S et al. (1998) Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Diabetes Care 21:1589–1595CrossRefPubMed
3.
Writing group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199–208CrossRef
4.
Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB (1992) Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74:1396–1400PubMed
5.
Lobo R, Pickar J, Wild R, Walsh B, Hirvonen E (1994) Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987–995PubMed
6.
Cagnacci A, Tuveri F, Cirillo R, Setteneri AM, Melis GB, Volpe A (1997) The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 28:163–167CrossRefPubMed
7.
Colacurci N, Zarcone R, Mollo A et al. (1998) Effects of hormone replacement therapy on glucose metabolism. Panminerva Medica 40:18–21PubMed
8.
Davidson M, Maki K, Marx P et al. (2000) Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 160:3315–3325CrossRefPubMed
9.
Hodis H, Mack W, Lobo R et al. (2001) Estrogen in the prevention of atherosclerosis. Ann Intern Med 135:939–953CrossRefPubMed
10.
Lobo R, Bush T, Carr B, Pickar J (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76:13–24CrossRefPubMed
11.
Goldman J, Ovadia J (1969) The effect of estrogen on intravenous glucose tolerance in women. Am J Obstet Gynecol 103:172–178CrossRefPubMed
12.
Spellacy W, Buhi W, Birk S (1972) The effect of estrogen on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 114:378–392CrossRefPubMed
13.
Ajabor L, Tsai C, Vela P, Yen S (1972) Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 113:383–387CrossRefPubMed
14.
De Cleyn K, Buytaert P, Coppens M (1989) Carbohydrate metabolism during hormonal substitution therapy. Maturitas 11:235–242CrossRef
15.
Godsland I, Gangar K, Walton C et al. (1993) Insulin resistance, secretion, and elimination in postmenopausal women receiving oral and transdermal hormone replacement therapy. Metabolism 42:846–853CrossRefPubMed
16.
O’Sullivan A, Ho K (1995) A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80:1783–1788
17.
Kimmerle R, Heinemann L, Heise T et al. (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36–42CrossRefPubMed
18.
Roo G, Stehouwer C, Meijer P et al. (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993–3000CrossRef
19.
Seed M, Sands R, McLaren M, Kirk G, Darko D (2000) The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pract 17:497–507CrossRefPubMed
20.
Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Yki-Jarvinen H (2000) Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 85:4663–4670PubMed
21.
Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT (1979) Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 133:525–536CrossRefPubMed
22.
Gabal L, Goodman-Gruen D, Barrett-Connor E (1997) The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Pub Health 87:443–445CrossRef
23.
Zhang Y, Howard B, Cowan L et al. (2002) The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women: the Strong Heart Study. Diabetes Care 25:500–504CrossRefPubMed
24.
Rossi R, Origlinani G, Modena M (2004) Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 27:645–649CrossRefPubMed
25.
Manson J, Rimm E, Colditz G et al. (1992) A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2:665–673CrossRefPubMed
26.
Kanaya A, Herrington D, Vittinghoff E et al. (2003) Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138:1–9CrossRefPubMed
27.
Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative Clinical Trial and Observational Study. Control Clin Trials 19:61–109CrossRef
28.
Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRef
29.
Block G, Woods M, Potosky A, Clifford C (1990) Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 43:1327–1335CrossRefPubMed
30.
Patterson R, Kristal A, Coates R et al. (1996) Low-fat diet practices of older women: prevalence and implications for dietary assessment. J Am Diet Assoc 96:670–679CrossRefPubMed
31.
Ainsworth B, Haskell W, Leon A et al. (1993) Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 25:71–80CrossRefPubMed
32.
Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
33.
Nabulsi A, Folsom A, White A et al. (1993) Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328:1069–1075CrossRefPubMed
34.
Troisi R, Cowie C, Harris M (2000) Hormone replacement therapy and glucose metabolism. Obstet Gynecol 96:665–670CrossRef
35.
Barrett-Connor E, Laakso M (1990) Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 10:531–534CrossRefPubMed
36.
Cucinelli F, Paparella P, Soranna L et al. (1999) Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140:215–223CrossRefPubMed
37.
Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA (1993) A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60:664–667CrossRefPubMed
38.
Sites C, Brochu M, Tchernof A, Poehlman E (2001) Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 50:835–840CrossRefPubMed
39.
Ryan A, Nicklas B, Berman D (2002) Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25:127–133CrossRefPubMed
40.
Roussel A-M, Bureau I, Favier M, Polansky M, Bryden N, Anderson R (2002) Beneficial effects of hormone replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women. Maturitas 42:63–69CrossRefPubMed
41.
Evans E, Van Pelt E, Binder E, Williams D, Ehsani A, Kohrt W (2001) Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women. J Appl Physiol 90:2033–2040CrossRefPubMed
42.
Duncan A, Lyall H, Roberts R et al. (1999) The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 84:2402–2407CrossRefPubMed
43.
Crook D, Godsland I, Hull J, Stevenson J (1997) Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 104:298–304CrossRefPubMed
44.
Walker RJ, Lewis-Barned NJ, Sutherland WH et al. (2001) The effects of sequential combined oral 17 beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 8:27–32CrossRefPubMed
45.
Fonseca E, Ochoa R, Galvan R, Hernandez M, Mercado M, Zarate A (1999) Increased serum levels of growth hormone and insulin-like growth factor-I associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 6:56–60CrossRefPubMed
46.
Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ, Lobo RA (1997) Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 67:57–62CrossRefPubMed
47.
Livingstone C, Collison M (2002) Sex steroids and insulin resistance. Clin Sci (Lond) 102:151–166
48.
Oh J-Y, Barrett-Connor E, Wedick N, Wingard D (2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25:55–60CrossRefPubMed
49.
Kalish G, Barrett-Connor E, Laughlin G, Gulanski B (2003) Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 88:1646–1652CrossRefPubMed
50.
Haffner S, Dunn J, Katz MS (1992) Relationship of sex-hormone-blinding globulin to lipid, lipoprotein, glucose and insulin concentrations in postmenopausal women. Metabolism 41:278–284CrossRefPubMed
51.
Lindstedt G, Lundberg P-A, Lapidus L, Lundgren H, Bengtsson B, Björntorp P (1991) Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. Diabetes 40:123–128CrossRefPubMed
52.
Haffner S, Valdez R, Morales P, Hazuda H, Stern M (1993) Decreased sex-hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 77:56–60PubMed
53.
Andersson B, Mattsson L, Hahn L et al. (1997) Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638–643PubMed
54.
Kaye S, Folsom A, Sprafka J, Prineas R, Wallace R (1991) Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329–334CrossRefPubMed
55.
Kehoe R, Wu S-Y, Leske M, Chylack L (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139:813–818CrossRefPubMed
56.
Midthjell K, Holmen J, Bjorndal A, Lund-Larsen P (1992) Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trondelag diabetes study. J Epidemiol Community Health 46:537–542CrossRefPubMedPubMedCentral
57.
Tretli S, Lund-Larsen P, Foss O (1982) Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health 36:269–273CrossRefPubMedPubMedCentral
58.
Kriegsman D, Penninx B, Eijk J van, Boeke A, Deeg D (1996) Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly: a study on the accuracy of patients’ self-reports and on determinants of inaccuracy. J Clin Epidemiol 49:1407–1417CrossRefPubMed
59.
Harris M, Flegal K, Cowie C et al. (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Study, 1988-1994. Diabetes Care 21:518–524CrossRefPubMed
60.
The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRef
61.
Kim C, Seidel K, Begier E, Kwok Y (2001) Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766–1771CrossRefPubMed
Metadata
Title
Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial
Authors
K. L. Margolis
D. E. Bonds
R. J. Rodabough
L. Tinker
L. S. Phillips
C. Allen
T. Bassford
G. Burke
J. Torrens
B. V. Howard
for the Women’s Health Initiative Investigators
Publication date
01-07-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1448-x

Other articles of this Issue 7/2004

Diabetologia 7/2004 Go to the issue

Article

Simple non-invasive assessment of advanced glycation endproduct accumulation

Article

Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy

Article

Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin-deficient diabetes mellitus in rats

Author’s Reply

Reply to Comment on: Hales CN, Ozanne SE (2003) For Debate: Fetal and early postnatal growth restriction lead to diabetes, the metabolic syndrome and renal failure

Article

Loss of beta cell function as fasting glucose increases in the non-diabetic range

Article

Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits